An Open-label, 36-week Extension Study on Amdoxovir at 500 mg Bid or 300 mg Bid in Combination With Zidovudine and Lopinavir/Ritonavir in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations. [EXTENSION OF 700194613]
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Amdoxovir (Primary) ; Lopinavir/ritonavir; Zidovudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- 09 Apr 2013 New trial record